The RAS/mitogen-activated protein kinase (MAPK) signaling cascade is commonly
dysregulated in human malignancies by processes driven by RAS or RAF oncogenes …

The aberrant activation of RAS-derived mitogen-activated protein kinase (MAPK) signaling
pathway plays a prominent role in tumorigenesis of an array of malignancies. The reasons …

Data accumulated over more than three decades demonstrate that the assembly of
macrocomplexes, mainly of dimers, is widespread among the members of the different tiers …

Abstract Hyperactive RAS/RAF/MEK/ERK signaling has a well-defined role in cancer
biology. Targeting this pathway results in complete or partial regression of most cancers. In …

Activating mutations in MAP2K1 can be seen in benign and intermediate-grade melanocytic
neoplasms with spitzoid morphology. We analyzed the clinical, histopathologic, and genetic …

Despite significant advances in cancer precision medicine, a significant hurdle to its broader
adoption remains the multitude of variants of unknown significance identified by clinical …

Aberrant activation of KRAS signaling is common in cancer, which has catalyzed heroic drug
development efforts to target KRAS directly or its downstream signaling effectors. Recent …

Activating mutations in mitogen-activated protein kinase kinase 1 (MAP2K1) are involved in
a variety of cancers, and may be classified according to their RAF dependence. Sensitivity to …

While the genomics of BRAF, NRAS, and other key genes influencing MAP kinase (MAPK)
activity have been thoroughly characterized in melanoma, mutations in MAP2K1 (MEK1) …

Specific alterations involving MAPK genes (MAP3K8 fusions, MAP3K3 fusions) have been
recently detected in a subgroup of spitzoid neoplasms that seem to constitute a distinctive …